



**Neuren (NEU) – ASX Announcement**

**8 September 2025**

## **Changes in securities interests of CEO & Managing Director**

In July 2025 Neuren's CEO & Managing Director, Jon Pilcher, paid \$2.8 million to Neuren to extinguish the loan attached to 1.5 million Loan Funded Shares, which was expiring after 5 years. At that time, he was restricted from selling any shares to fund the loan repayment and taxes, pending Acadia's Q2 2025 earnings announcement, followed by Neuren's H1 2025 results announcement on 27 August 2025.

As detailed in the attached Change of Director's Interest Notice, 398,207 shares have now been sold to a small number of institutional investors.

The loan repayment and share sale transactions resulted in the following:

- Neuren's cash and share capital increased by \$2.8 million.
- The CEO's quoted shareholding increased from 0.4 million shares to 1.5 million shares, placing him in the top 15 beneficial holders and top 10 registered holders.
- Neuren's institutional shareholdings increased by 0.4 million shares.

### **About Neuren**

Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, programs have been granted "orphan drug" designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) and Health Canada for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.

Neuren's second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.

### **Contact:**

investorrelations@neurenpharma.com

Jon Pilcher, CEO: +61 438 422 271

### **ASX Listing Rules information**

This announcement was authorized to be given to the ASX by the CEO & Managing Director of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Neuren Pharmaceuticals Limited
ARBN:	111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jonathan Pilcher
Date of last notice	22 July 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mrs J L Pilcher (spouse)
Date of change	8 September 2025
No. of securities held prior to change	Direct interest in 1,500,000 Ordinary shares and indirect interest in 398,207 Ordinary shares
Class	Ordinary shares
Number acquired	
Number disposed	398,207
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$20.00 per share

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

No. of securities held after change	Direct interest in 1,500,000 Ordinary shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market crossing

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

#### Part 3 – <sup>+</sup>Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	Not applicable
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

---

<sup>+</sup> See chapter 19 for defined terms.